- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00044122
Study of Factors Regulating Mast Cell Proliferation
Regulation of the Proliferation and Survival of Normal and Neoplastic Human Mast Cells
This study will examine growth factors that promote and inhibit mast cell proliferation resulting in mastocytosis, a disease of excessive mast cells in the body. These cells can release chemicals that cause itching, blisters, flushing, bone pain and abdominal pain.
Patients up to 80 years of age with mastocytosis may be eligible for this 1-day study. Participants will have one visit at NIH lasting up to 8 hours, during which they will undergo the following tests and procedures:
- Medical history and physical examination.
- Laboratory studies, if medically indicated.
- Blood tests to identify genetic changes important in the growth, development, and functioning of mast cells.
- Bone marrow aspiration and biopsy.
For the bone marrow procedure, the skin over the hipbone and the outer surface of the bone itself are numbed with local anesthesia. Then, a special needle is inserted into the hipbone and about 1 tablespoon of bone marrow is drawn into a syringe. Another needle is inserted into the same area to collect a small piece of the bone marrow. Additional procedures may include allergen testing, urinalysis, and 24-hour urine collection.
Participants will receive an evaluation of their mastocytosis.
Study Overview
Status
Conditions
Detailed Description
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Hye Jeong C Bolan, R.N.
- Phone Number: (301) 594-1233
- Email: bolanhy@mail.nih.gov
Study Contact Backup
- Name: Hirsh D Komarow, M.D.
- Phone Number: (301) 594-2197
- Email: komarowh@mail.nih.gov
Study Locations
-
-
Maryland
-
Bethesda, Maryland, United States, 20892
- Recruiting
- National Institutes of Health Clinical Center
-
Contact:
- For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)
- Phone Number: TTY dial 711 800-411-1222
- Email: ccopr@nih.gov
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
- PATIENT PARTICIPANT INCLUSION CRITERIA:
Participants with mastocytosis zero to 80 years of age may participate in telehealth visits, and two to 80 years of age may participate on-site at NIH Clinical Center.
Histologic evidence of increased mast cell number by bone marrow and/or skin biopsy or documentation of mastocytosis in the skin
supported with a photograph of diagnostic skin lesions
Must be under the care of a primary care physician to be enrolled.
Ability to provide informed consent.
PATIENT PARTICIPANT EXCLUSION CRITERIA:
Anemia with hemoglobin less than 8 g/dL, hematocrit less than 24.
Any condition that in the opinion of the investigator contraindicates participation in this study.
RELATIVE INCLUSION CRITERIA:
Two to 80 years of age.
A biological relative without the diagnosis of mastocytosis by skin examination or histologic evidence in a skin or bone marrow biopsy
Participant has a primary medical care provider outside the NIH
Ability to provide informed consent.
RELATIVE EXCLUSION CRITERIA:
Any condition that in the opinion of the investigator contraindicates participation in this study.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
|---|
|
Adult Relatives
Relatives of patient with mastocytosis
|
|
Adults with Mastocytosis
Adults with documented mastocytosis
|
|
Pediatric Patients with Mastocytosis
Pediatric patients with documented mastocytosis
|
|
Pediatric Relatives
Pediatric relatives of patients with mastocytosis
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
To obtain normal and neoplastic human mast cells from the bone marrow and peripheral blood of patients with mastocytosis in order to study the regulation of the proliferation and survival of these cells, and to assess the extent and classificati...
Time Frame: Patients return to NIH as necessary
|
continuing collection of cells from subjects with mastocytosis for ongoing experimentation in laboratory
|
Patients return to NIH as necessary
|
Collaborators and Investigators
Investigators
- Principal Investigator: Hirsh D Komarow, M.D., National Institute of Allergy and Infectious Diseases (NIAID)
Publications and helpful links
General Publications
- Carter MC, Metcalfe DD, Komarow HD. Mastocytosis. Immunol Allergy Clin North Am. 2014 Feb;34(1):181-96. doi: 10.1016/j.iac.2013.09.001. Epub 2013 Oct 7.
- Chan EC, Bai Y, Kirshenbaum AS, Fischer ER, Simakova O, Bandara G, Scott LM, Wisch LB, Cantave D, Carter MC, Lewis JC, Noel P, Maric I, Gilfillan AM, Metcalfe DD, Wilson TM. Mastocytosis associated with a rare germline KIT K509I mutation displays a well-differentiated mast cell phenotype. J Allergy Clin Immunol. 2014 Jul;134(1):178-87. doi: 10.1016/j.jaci.2013.12.1090. Epub 2014 Feb 28.
- Cruse G, Metcalfe DD, Olivera A. Functional deregulation of KIT: link to mast cell proliferative diseases and other neoplasms. Immunol Allergy Clin North Am. 2014 May;34(2):219-37. doi: 10.1016/j.iac.2014.01.002. Epub 2014 Mar 12.
- Wilson TM, Maric I, Simakova O, Bai Y, Chan EC, Olivares N, Carter M, Maric D, Robyn J, Metcalfe DD. Clonal analysis of NRAS activating mutations in KIT-D816V systemic mastocytosis. Haematologica. 2011 Mar;96(3):459-63. doi: 10.3324/haematol.2010.031690. Epub 2010 Dec 6.
- Krausfeldt LE, Cao V, Rodrigues R, Henderson WA, Eisch R, Scott LM, Metcalfe DD, Komarow HD. Evidence for dysbiosis in the gut microbiome of patients with systemic mastocytosis. J Allergy Clin Immunol Glob. 2025 Oct 9;5(1):100578. doi: 10.1016/j.jacig.2025.100578. eCollection 2026 Jan.
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 020277
- 02-I-0277
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Mastocytosis
-
University Hospital, ToulouseNot yet recruiting
-
Fondazione IRCCS Policlinico San Matteo di PaviaRecruitingSystemic Mastocytosis | Cutaneous MastocytosisItaly
-
Blueprint Medicines CorporationActive, not recruitingIndolent Systemic MastocytosisCanada, United States, Spain, United Kingdom, Germany, Belgium, Switzerland, Italy, Netherlands, Denmark, France, Norway, Sweden
-
Blueprint Medicines CorporationRecruitingIndolent Systemic MastocytosisGermany
-
Cogent Biosciences, Inc.Active, not recruitingMastocytosis | Mastocytosis, Systemic | SSM | Mastocytosis, Indolent | Smoldering Systemic Mastocytosis | ISM | BMM | Bone Marrow MastocytosisUnited States, Canada, Spain, United Kingdom, Australia, Norway, Italy, Switzerland, Germany, Ireland, Netherlands, Belgium, Czechia, France, Poland
-
AB ScienceRecruitingIndolent Systemic MastocytosisFrance, Netherlands, Germany, United Kingdom, Russian Federation, Poland, Romania, Ukraine
-
Allakos Inc.CompletedIndolent Systemic MastocytosisGermany
-
Blueprint Medicines CorporationAnalysis Group, Inc.CompletedMast Cell Leukemia | Aggressive Systemic Mastocytosis | Advanced Systemic Mastocytosis | Systemic Mastocytosis With an Associated Hematological NeoplasmUnited States, Austria, Germany, Spain, United Kingdom
-
Blueprint Medicines CorporationRecruitingIndolent Systemic Mastocytosis | Smoldering Systemic MastocytosisUnited States, Spain, Belgium, Australia, France, Netherlands, Norway, Greece, United Kingdom, Switzerland, Sweden, Austria, Germany, Italy, Portugal, Czechia, Argentina, Poland, Turkey (Türkiye)
-
University Hospital, ToulouseCompletedIndolent Systemic Mastocytosis | Cutaneous MastocytosisFrance